CLOSED STUDIES
Ovarian cancer
ENGOT-ov39/GEICO 63-O/IMAGYN 050 (Y García)
A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
ENGOT-ov29/GEICO 58-O/ATALANTE (A Oaknin)
A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
ENGOT-ov40/GEICO 71-R/Expression VI (P Barretina)
Caroline meets HANNA – Holistic Analysis of LoNgterm-survival with OvariaNCAncer.
GEICO 66-O/OLATRA (I Romero)
Phase II studyofOlaparib as maintenanceTherapyafter response totrabectedin-pegylatedliposomaldoxorubicin in recurrentovarian carcinoma.
ENGOT-ov25/GEICO 48-O/PAOLA-1 (A González)
Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
GEICO 29-O/INOVATYON (A Poveda)
Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
ENGOT OV27/GEICO 52-O/MORAB (A González)
Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.
ENGOT-ov26/GEICO 54-O/PRIMA (A González)
A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.
GEICO 37-O/NOVA (Y García)
Ensayo clínico fase II de quimioterapia neoadyuvante con o sin Bevacizumab en pacientes con cáncer de ovario.
GEICO 31-O/NOVA (JM Del Campo)
F III, mantenimiento con niraparib vs placebo en recaída platino sensible.
ENGOT ov21/GEICO 39-O/SOLO-2 (A Poveda)
F III Olaparib vs placebo de mantenimiento tras recaída platino-sensible.
GEICO 30-Q/DESKTOP III (A Poveda/ S Martínez)
F III cirugía o no en la recaída platino sensible.
GEICO 33-O/PENELOPE (A González)
F III QT +/- pertuzumab en platino-resistente.
GEICO 42-R/ROSE (A González)
Estudio retrospectivo sobre tratamiento del cáncer de ovario.
GEICO 44-R/RETRO-ROC (I Romero)
Estudio post-autorización observacional restrospectivo y multicéntrico de la combinación con trabectedina y doxorubicinaliposomalpegilada (DLP) en cáncer de ovario recidivante.
CLINICAL TRIAL CODE: GEICO 1302 – ENGOT OV 11 – Array 162-311
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
CLINICAL TRIAL CODE: GEICO 1303 – ENGOT OV 16- NOVA (ENGOT)
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
ENGOT – OV-2b / TRINOVA 3 /GEICO-1201
TRINOVA – A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
MM-121 / GEICO 1202
Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers.
NCIC-OV 21 / GEICO-0902
Phase II-III Study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus Paclitaxel in patients with ovarian epithelial carcinoma subjected to optimum cytoreductive surgery subsequent to neoadyuvant intravenous chemotherapy.
GEICO 1001 – CATUMAXOMAB
Phase II trial to evaluate the efficacy and safety of catumaxomab as a consolidation treatment for patients with an ovarian or fallopian tube epithelial carcinoma, or a primary peritoneal carcinoma in second or third complete clinical remission.
AGO-OVAR 12 / GEICO-1003
Phase III study, multicentric, randomized, double-blind to evaluate the efficacy and security of BIBF 1120 in combination with carboplatin and paclitaxel compared with placebo combined with carboplatin and paclitaxel in patients with advanced ovarian cancer.
GEICO-1002
Phase II non-controlled, multi-center, prospective clinical trial to determine the clinical benefit and toxicity of Pazopanib, a multi-target inhibitor of receptors with tyrosine-kinase activity (VEGFR -1, -2 , -3, PDGFR-α and β and C-Kit), in platinum-resistant patients with advanced ovarian cancer.
ICON-6 / GEICO-1101
Gynaecologic Cancer Intergroup double-blind, controlled, multicenter clinical trial of Cediranib (AZD 2171), in combination either with platinum-based chemotherapy or as the sole agent in maintenance therapy, in women with ovarian cancer who have relapsed over 6 months after termination of a platinum-based first-line treatment.
AURELIA / GEICO 0904
AURELIA: Phase III multi-centre, open, randomized clinical trial, with two treatment groups, of bevacizumab in combination with chemotherapy versus chemotherapy alone in patients with epithelial ovarian cancer or platinum-resistant fallopian tube or primary peritoneal carcinoma.
GEICO 0901 / AGO-OVAR 16
Phase III study to evaluate the efficacy and safety of pazopanib as monotherapy versus placebo amongst women with epithelial ovarian, fallopian tube or peritoneal primary cancer who have not progressed after first-line chemotherapy.
GEICO 0905 – OCTAVIA
A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.
GEICO 0802/HECTOR-PHASE III-2006
Topotecan plus carboplatin versus the standard treatment (paclitaxel plus carboplatin or gemcitabine plus carboplatin) in the treatment of platinum-sensitive relapsing patients with peritoneal carcinoma, fallopian tube carcinoma or epithelial ovarian carcinoma.
GEICO 0804-R
Bevacizumab database in Ovarian Cancer relapses.
GEICO 0801-T
Retrospective study of biomarkers in Epithelial Ovarian Cancer.
GEICO 0803-R
Feasibility and toxicity of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.
GEICO 0701/ICON-7
Multi-centre, randomized, two-arm “Gynaecologic Cancer InterGroup” study to add bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients suffering from epithelial ovarian cancer.
GEICO 0702-T/TOPO IIA
Determination of the expression of TOPO IIA in ovarian carcinoma samples of patients treated with pegylated liposomal doxorubicin.
GEICO 0703/MIMOSA
Multi-centre, randomized, double-blind, placebo-controlled clinical trial to evaluate maintenance treatment with abagovomab in patients suffering from epithelial ovarian carcinoma after complete response to first-line chemotherapy.
GEICO 0104
Phase II randomized study of the carboplatin-gemcitabine doublet followed by carboplatin-paclitaxel versus carboplatin-paclitaxel in platinum-sensitive relapse patients with ovarian carcinoma, primary peritoneal carcinomatosis or fallopian tube carcinoma.
GEICO 0101
Phase III clinical trial to evaluate treatment with the combination of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus paclitaxel plus carboplatin as the first-line treatment in women with a recent diagnosis of advanced epithelial ovarian cancer.
GEICO 0103
Phase II study with Gemcitabine in prolonged infusion in patents with advanced platinum-resistant epithelial ovarian cancer.
GEICO CO22
Validation by GEICO of CAELYX in patients with epithelial ovarian cancer.
GEICO 0199
Phase II randomized clinical trial (with assessment of quality of life) of carboplatin versus the combination of taxol and carboplatin in platinum-sensitive patients with ovarian cancer relapse.
GEICO 0299/EORTC 55981/NSGO
Randomized clinical trial of Paclitaxel / Epirubicin / Carboplatin in combination (TEC) vs. Paclitaxel / Carboplatin (TC) in the treatment of women with advanced ovarian cancer.
